Shares of Regeneron are down $74.38, or over 9%, to $710.00 after the FDA issued a Complete Response Letter, or CRL, for the Biologics License Application, or BLA, for aflibercept 8 mg for the treatment of patients with wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on REGN:
- REGN, CTLT Continue Sliding Following FDA Rejection of Eylea Drug
- Regeneron Stock (NASDAQ:REGN) Sinks; FDA Snubs Higher-Dose Eye Drug
- Regeneron to resume trading at 3:15 pm ET
- Regeneron announces top-line, two-year data for aflibercept 8 mg PHOTON trial
- FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler